In a filing, Castle Biosciences Inc revealed its Pres. & Chief Exec. Officer MAETZOLD DEREK J unloaded Company’s shares for reported $14177.0 on Apr 23 ’24. In the deal valued at $20.11 per share,705 shares were sold. As a result of this transaction, MAETZOLD DEREK J now holds 9,683 shares worth roughly $0.24 million.
Then, MAETZOLD DEREK J sold 421 shares, generating $8,466 in total proceeds. Upon selling the shares at $20.11, the Pres. & Chief Exec. Officer now owns 64,997 shares.
Before that, MAETZOLD DEREK J sold 3,263 shares. Castle Biosciences Inc shares valued at $66,402 were divested by the Pres. & Chief Exec. Officer at a price of $20.35 per share. As a result of the transaction, MAETZOLD DEREK J now holds 9,752 shares, worth roughly $0.24 million.
Guggenheim initiated its Castle Biosciences Inc [CSTL] rating to a Buy in a research note published on December 14, 2023; the price target was $25. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early January with a ‘”a Sector outperform”‘ rating. Stephens began covering CSTL with “an Overweight” recommendation on January 07, 2022. Lake Street started covering the stock on April 30, 2021. It rated CSTL as “a Buy”.
Price Performance Review of CSTL
On Friday, Castle Biosciences Inc [NASDAQ:CSTL] saw its stock jump 6.52% to $24.33. Over the last five days, the stock has gained 19.62%. Castle Biosciences Inc shares have risen nearly 12.74% since the year began. Nevertheless, the stocks have risen 6.20% over the past one year. While a 52-week high of $26.70 was reached on 05/03/24, a 52-week low of $9.26 was recorded on 02/29/24. SMA at 50 days reached $20.89, while 200 days put it at $19.28. A total of 0.84 million shares were traded, compared to the trading of 0.32 million shares in the previous session.
Levels Of Support And Resistance For CSTL Stock
The 24-hour chart illustrates a support level at 22.77, which if violated will result in even more drops to 21.20. On the upside, there is a resistance level at 25.90. A further resistance level may holdings at 27.47. The Relative Strength Index (RSI) on the 14-day chart is 70.07, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.53, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 21.32%. Stochastics %K at 86.01% indicates the stock is a selling.
The most recent change occurred on November 10, 2020 when KeyBanc Capital Markets began covering the stock and recommended ‘”an Overweight”‘ rating along with a $70 price target.
